Pharmacokinetics of 1M gadobutrol in patients with chronic renal failure

Investigative Radiology

Volumn 35, Issue 1, 2000, Pages 35-40

  Tombach, Bernd ^a   Bremer, Christoph ^a   Reimer, Peter ^a   Schaefer, Roland M ^b   Ebert, Wolfgang ^c   Geens, Viviane ^c   Heindel, Walter ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b INST OF REPRO MED OF THE UNIV   (Germany)

^c BAYER PHARMA AG   (Germany)

Author keywords

Gadobutrol; MR contrast agents; Pharmacokinetics; Renal impairment

Indexed keywords

GADOBUTROL;

ADULT; ARTICLE; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTRAST ENHANCEMENT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG URINE LEVEL; FEMALE; HUMAN; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0033982129     PISSN: 00209996     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004424-200001000-00004     Document Type: Article

References (22)

1. Staks T, Schumann-Giampieri G, Frenzel T, et al. Pharmacokinetics, dose proportionality, and tolerability of gadobutrol after single intravenous injection in healthy volunteers. Invest Radiol 1994;29: 709-715.
2. Mühler A. Assessment of myocardial perfusion using contrast-enhanced MR imaging: Current status and future developments. MAGMA 1995;3:21-33.
3. Heiland S, Benner T, Reith W, Forsting M, Sartor K. Perfusionweighted MRI using gadobutrol as a contrast agent in a rat stroke model. J Magn Reson Imaging 1997;7:1109-1115.
4. Schuhmann-Giampieri G, Krestin G. Pharmacokinetics of Gd-DTPA in patients with chronic renal failure. Invest Radiol 1991;26:975-979.
5. Joffe P, Thomsen HS, Meusel M. Pharmacokinetics of gadodiamide injection in patients with severe renal insufficiency and patients undergoing hemodialysis or continuous ambulatory peritoneal dialysis. Acad Radiol 1998;5:491-502.
6. Reinton V, Berg KJ, Svaland M, et al. Pharmacokinetics of gadodiamide in patients with moderately impaired renal function. Acad Radiol 1994;1:56-61.
7. La France ND, Parker JR, Lucas TR, et al. Clinical investigation of the safety and pharmacokinetics of gadoteridol injection in renally impaired patients requiring hemodialysis [abstract]. Proceedings of the Third Meeting of the International Society for Magnetic Resonance in Medicine, 1995:287.
8. Chacuat A, Molinier P, Bonnemain B, et al. Pharmacokinetics and tolerance of Gd-DOTA (Dotarem) in healthy volunteers and in patients with chronic renal failure. Eur Radiol 1992;156:326-329.
9. Vogler H, Platzek J, Schuhmann-Giampieri G, et al. Preclinical evaluation of gadobutrol: A new, neutral, extracellular contrast agent for magnetic resonance imaging. Eur J Radiol 1995;21:1-10.
10. Investigator's Brochure. Schering AG, Berlin, Germany. June 5, 1998: 15-18.
11. Weinmann HJ, Platzek J, Radüchel B, et al. A new macrocyclic gadolinium chelate as a contrast agent for MRI. Eur Radiol 1993(3 suppl):126.
12. Chasson AL, Grady HJ, Stanley MA. Determination of creatinine by means of automatic chemical analysis. Am J Clin Pathol 1961;35: 83-88.
13. Hofmann B, Fischer CO, Lawaczeck R, et al. Gadolinium neutron capture therapy (GdNCT) of melanoma cells and solid tumors with the magnetic resonance imaging contrast agent gadobutrol. Invest Radiol 1999;34:126-133.
14. McLachlan SJ, Eaton S, De Simone DN. Pharmacokinetic behavior of gadoteridol injection. Invest Radiol 1992;27(Suppl 1):12-15.
15. Van Wagoner M, O'Toole M, Worah D, et al. A phase I clinical trial with gadodiamide injection, a nonionic magnetic resonance imaging enhancement agent. Invest Radiol 1991;26:980-986.
16. Le Mignon MM, Chambon C, Warrington S, et al. Gd-DOTA, pharmacokinetics and tolerability after intravenous injection into healthy volunteers. Invest Radiol 1990;25:933-937.
17. Weinmann HJ, Laniado M, Mützel W. Pharmacokinetics of Gd-DTPA dimeglumine after intravenous injection into healthy volunteers. Physiol Chem Phys 1984;16:167-172.
18. Frank JA, Choyke PL, Girton ME, et al. Gadopentetate dimeglumine clearance in renal insufficiency in rabbits. Invest Radiol 1990;25: 1212-1216.
19. Kirchin MA, Pirovano GP, Spinazzi A. Gadobenate dimeglumine (Gd-BOPTA): An overview. Invest Radiol 1998;33:798-809.
20. Krestin GP, Schuhmann-Giampieri G, Haustein J, et al. Functional dynamic MRI, pharmacokinetics and safety of Gd-DTPA in patients with impaired renal function. Eur Radiol 1992;2:16-23.
21. Krahe Th, Götz R, Lackner K, et al. Pharmakokinetik von Gadolinium-DTPA bei dialysepflichtiger chronischer Niereninsuffizienz. Fortschr Röntgenstr 1992;156:523-526.
22. Tombach B, Bremer CB, Schaefer RM, et al. Safety of 1 M gadobutrol as a new MR contrast agent for first-pass and conventional investigations: Phase III clinical trial in patients with chronically impaired renal function. Radiology 1998;209:445.